Radiation lung injury after radiotherapy in NSCLC
Conditions
Interventions
treatment group:On the basis of the conventional clinical treatment for the primary disease, the combined study drug was used. The study drug administration regimen was as follows: the study drug was
control group:Treatment of primary illnesses using conventional clinical protocols.
Sponsors
Zhangjiakou city first hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years at the time of screening; 2. Histologically/cytologically confirmed diagnosis of NSCLC; 3. TNM staging of stage II or III according to the International Association for the Study of Lung Cancerstaging manual (8th edition); 4. Unsuitable for or unable to tolerate surgery; 5. WHO performance status of 0 or 1 at randomization; 6. No previous radiation therapy; 7. Be able to swallow gelatin pills; 8. Suitable for completing pulmonary function tests; 9. Volunteered to participate in the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Expected life expectancy of <6 months at randomization; 2. Severe cardiovascular, cerebrovascular, neurological diseases, infections, epilepsy, active peptic ulcer, psychological disorders, etc.; 3. Abnormal liver function (transaminases elevated to 2.5 times or more the upper limit of normal); 4. Abnormal renal function (creatinine clearance <30 ml/min) or requiring dialysis; 5. Recent anticoagulation therapy or combination of deep vein thrombosis, pulmonary embolism, heart attack and cerebral infarction, etc.; 6. Antifibrotic therapy within 1 month; 7. Allergy or intolerance to therapeutic drugs and ingredients; 8. Pregnant or breastfeeding women; 9. Others who, in the judgement of the researcher, are not suitable to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of grade 2 or higher RP; | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of RP;Therapeutic efficacy of RP;The effectiveness of tumor treatment; | — |
Countries
China
Contacts
Public ContactCui Ai
Beijing Chaoyang Hospital, Capital Medical University
Outcome results
None listed